Clinical Trial

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I/II trial studies the side effects and best dose of ABBV-383 and to see how well it works in treating patients with Waldenström macroglobulinemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). ABBV-383 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2036-03-25 -> 2036-10-25 2026-07-09
minor Completion pushed: 2038-03-25 -> 2038-10-25 2026-07-09
Trial Details
NCT Number NCT07420959
Lead Sponsor Mayo Clinic
Conditions Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Enrollment 38 participants
Start Date 2026-10-25
Primary Completion 2036-10-25 (estimated)
Study Completion 2038-10-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-08